Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6256974 | 1.00 | FFAR3 (0.33) | FFAR3TSHRNFKB1CYP2C19USP2 | |
| Hydrochloric Acid SCHEMBL23668258 | 0.98 | FFAR3 (0.32) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL23525345 | 0.93 | FFAR3 (0.32) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL10589251 | 0.80 | PARP1 (0.31) | — | |
| SCHEMBL4635176 | 0.80 | FFAR3 (0.32) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL14762049 | 0.76 | FFAR3 (0.36) | FFAR3TSHRNFKB1CYP2C19USP2 | |
| SCHEMBL845600 | 0.74 | — | — | |
| SCHEMBL9762967 | 0.74 | — | — | |
| SCHEMBL29549012 | 0.74 | — | — | |
| SCHEMBL845602 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| US-20250147048-A1 | METHODS OF DIAGNOSTIC SCREENING AND EARLY DETECTION OF ADENOMYOSIS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-05-08 | — | — | US | claimed |
| US-5665371-A | SIDE EFFECT REDUCTION | HOERRMANN WILHELM (DE) | 1997-09-09 | — | — | US | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250147048-A1 | METHODS OF DIAGNOSTIC SCREENING AND EARLY DETECTION OF ADENOMYOSIS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-05-08 | — | — | US | disclosed |
| WO-2024015934-A2 | METHODS OF DIAGNOSTIC SCREENING AND EARLY DETECTION OF ADENOMYOSIS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20220102000-A1 | PREDICTING BLOOD METABOLITES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-03-31 | — | — | US | disclosed |
| CN-112546244-A | Fibroblast growth factor receptor2 specific peptide reagents and methods | 密执安州立大学董事会 | 2021-03-26 | — | — | CN | disclosed |
| CN-111107881-A | Fibroblast growth factor receptor2 specific peptide reagents and methods | 密执安州立大学董事会 | 2020-05-05 | — | — | CN | disclosed |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | disclosed |
| US-5733539-A | PLANT FERMENTED MATRIX MATERIAL CONTAINIGN AMINO ACID | RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) | 1998-03-31 | — | — | US | disclosed |
| EP-0796564-A1 | FEED FOR FISHES AND SHELLFISHES | RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) | 1997-09-24 | — | — | EP | disclosed |
| EP-0311193-B1 | Antifungal fermentation product | MERCK & CO INC (US) | 1993-12-01 | — | — | EP | disclosed |
| EP-0359529-B1 | METHOD FOR THE CONTROL OF PNEUMOCYSTIS CARINII | MERCK & CO. INC. (US) | 1993-03-03 | — | — | EP | disclosed |
| US-5166135-A | Administering cyclohexapeptide antibiotic; AIDS | MERCK & COMPANY, INC. (US) | 1992-11-24 | — | — | US | disclosed |
| US-4968608-A | CYCLIC PEPTIDE ANTIBIOTIC FROM ZALERION | MERCK & CO., INC. (US) | 1990-11-06 | — | — | US | disclosed |
| US-4931352-A | Antifungal fermentation product | MERCK & CO., INC. (US) | 1990-06-05 | — | — | US | disclosed |
| EP-0359529-A1 | Method for the control of pneumocystis carinii | MERCK & CO. INC. (US) | 1990-03-21 | — | — | EP | disclosed |
| EP-0311194-A2 | Process for antifungal fermentation product and culture | MERCK & CO. INC. (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0311193-A2 | Antifungal fermentation product | MERCK & CO. INC. (US) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | PREP, PRAP1, VHL | FFAR3 4307/4885TSHR 4390/4885NFKB1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.